Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of stage IIIB (and is not a
             candidate for definitive multimodality therapy) or IV ALK-positive NSCLC.

          -  Patients may have received one prior treatment regimen with crizotinib (all other ALK
             inhibitors are excluded).

          -  Patients may have received prior chemotherapy, biologic therapy, or other
             investigational agents. ALK inhibitors other than crizotinib are excluded.

          -  Patient has a World Health Organization (WHO) performance status 0-2.

        Exclusion Criteria:

          -  Prior treatment with an ALK inhibitor other than crizotinib.

          -  History of carcinomatous meningitis.

          -  Presence or history of a malignant disease other than an ALK-positive advanced tumor
             that has been diagnosed and/or required therapy within the past 3 years.

          -  Clinically significant, uncontrolled heart disease and/or recent cardiac event (within
             6 months)

          -  Patient has history of interstitial lung disease or interstitial pneumonitis,
             including clinically significant radiation pneumonitis (i.e., affecting activities of
             daily living or requiring therapeutic intervention).

          -  Patient has other severe, acute, or chronic medical conditions

          -  Patient is currently receiving treatment with warfarin sodium (Coumadin®) or any other
             coumarin-derivative anticoagulants.